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Peroxynitrite is thought to be a nitric oxide-derived
neurotoxic effector molecule involved in the disruption
of key energy-related metabolic targets. To assess the
consequences of such interference in cellular glucose
metabolism and viability, we studied the possible mod-
ulatory role played by peroxynitrite in glucose oxida-
tion in neurons and astrocytes in primary culture. Here,
we report that peroxynitrite triggered rapid stimulation
of pentose phosphate pathway (PPP) activity and the
accumulation of NADPH, an essential cofactor for glu-
tathione regeneration. In contrast to peroxynitrite, ni-
tric oxide elicited NADPH depletion, glutathione oxida-
tion, and apoptotic cell death in neurons, but not in
astrocytes. These events were noticeably counteracted
by pretreatment of neurons with peroxynitrite. In an
attempt to elucidate the mechanism responsible for this
PPP stimulation and neuroprotection, we found evi-
dence consistent with both exogenous and endogenous
peroxynitrite-mediated activation of glucose-6-phos-
phate dehydrogenase (G6PD), an enzyme that catalyzes
the first rate-limiting step in the PPP. Moreover, func-
tional overexpression of the G6PD gene in stably trans-
formed PC12 cells induced NADPH accumulation and
offered remarkable resistance against nitric oxide-me-
diated apoptosis, whereas G6PD gene-targeted anti-
sense inhibition depleted NADPH levels and exacer-
bated cellular vulnerability. In light of these results, we
suggest that G6PD activation represents a novel role for
peroxynitrite in neuroprotection against nitric oxide-
mediated apoptosis.
Nitric oxide (NO) is a short-lived physiological neural mes-
senger involved in diverse biologically relevant functions (see
Ref. 1 for a review). In neurons and astrocytes, NO is produced
through the activation of a constitutive calcium-dependent
neuronal nitric-oxide synthase and participates in the signal-
ing pathway, leading to rises in cGMP levels (2–4). In addition,
astrocytes have the ability to form NO in a calcium-indepen-
dent fashion that requires prior transcriptional expression of
the inducible nitric-oxide synthase isoform by lipopolysaccha-
ride (LPS)1 and/or certain cytokines (5, 6). Under certain neu-
ropathological situations, however, excessive or inappropriate
NO biosynthesis (nitrosative stress) is followed by a reaction of
NO with superoxide (O2
.) to form peroxynitrite (ONOO), a
pro-oxidant molecule thought to execute the neurotoxic NO-
mediated responses (7–10).
With respect to the neurotoxicity elicited by inappropriate
NO biosynthesis, the intracellular content of glutathione
(GSH) appears to play a key role in dictating cellular vulnera-
bility. Thus, NO and peroxynitrite potently oxidize sulfhydr-
yls, including GSH (11, 12). Accordingly, neuronal GSH oxida-
tion has been proposed to be a contributing factor leading to the
mitochondrial damage and neurotoxicity associated with nitro-
sative stress (13–15). Unlike neurons, astrocytes are cells that
efficiently maintain GSH in its reduced redox status, even
under conditions of excessive endogenous NO formation (16,
17). However, the mechanism(s) involved in such different cel-
lular abilities to restore GSH levels is an issue that remains to
be elucidated.
Hepatocytes are cells prone to hydrogen peroxide (H2O2)-
mediated activation of glucose-6-phosphate dehydrogenase
(G6PD), an enzyme that catalyzes the first rate-limiting step in
the oxidative branch of the pentose phosphate pathway (PPP)
(18, 19). Furthermore, stimulation of this pathway in neurons
(20) and astrocytes (21) has been proposed to elicit a protective
action against H2O2 toxicity through the PPP activity-medi-
ated production of NADPH, a cofactor necessary for GSH re-
generation from oxidized glutathione (GSSG) (22, 23). A simi-
lar protective mechanism has also been reported for Jurkat
human T cells, where targeted inactivation of transaldolase,
i.e. the rate-limiting step in the non-oxidative branch of the
PPP, prevents the GSH oxidation and apoptosis caused by a
number of pro-oxidant compounds, including NO (24).
In keeping with the above-mentioned studies, we reported
previously that glucose utilization through the PPP in LPS-
stimulated astrocytes offers self-protection against endogenous
NO-mediated GSH oxidation (25). Because LPS-stimulated
astrocytes synthesize O2
. through inducible nitric-oxide
synthase-dependent activity (26), we wondered whether the
peroxynitrite thus formed could be an effector molecule directly
involved in the modulation of PPP activity. Here, we report
that peroxynitrite elicited a rapid stimulation of PPP activity in
both neurons and astrocytes through the activation of G6PD.
Furthermore, we report strong evidence suggesting that such a
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phenomenon would be involved in the protection of neurons
against NO-mediated glutathione oxidation and apoptosis.
EXPERIMENTAL PROCEDURES
Materials
Peroxynitrite was synthesized and quantified spectrophotometrically
(302  1670 M
1 cm1) as previously described (27). Alkaline stock
solutions with an approximate ONOO concentration of 0.5 M were
stable at 70 °C for at least 3–4 months. Nitric oxide was purchased
from Al Air Liquide (Madrid, Spain) and extemporarily dissolved in
O2-free water by 20-min bubbling until saturation. The concentration of
NO solutions was estimated with an NO electrode (ISO-NO, World
Precision Instruments, Inc.) using the NO-saturated solution as a
standard (2 mM NO). Dulbecco’s modified Eagle’s medium (DMEM),
LPS, dihydrorhodamine 123, TEMPOL (4-hydroxy-2,2,6,6-tetrameth-
ylpiperidine-1-oxyl), and hemoglobin were obtained from Sigma. Fetal
calf serum was purchased from Roche Diagnostics (Heidelberg, Germa-
ny). Type I rat tail collagen was from BD Biosciences. D-[1-14C]Glucose
and D-[6-14C]glucose were obtained from ARC Inc. (St. Louis, MO), and
[-32P]dCTP and Hybond® nitrocellulose membranes were from Amer-
sham Biosciences (Buckinghamshire, UK). The peroxynitrite donor
SIN-1 (3-morpholinosydnonimine) and the NO donor diethylenetri-
amine (DETA)-NO were purchased from Alexis Corp. (San Diego, CA).
2-Vinylpyridine was from Aldrich (Gillingham-Dorset, UK). Plastic tis-
sue culture dishes were purchased from Nunc (Roskilde, Denmark).
Anti-G6PD antiserum was a generous gift from Prof. Matilde V. Ursini
(Instituto Internazionale di Genetica e Biofisica, Consiglio Nazionale
delle Ricerche, Naples, Italy). Anti-green fluorescent protein (GFP)
antibody was obtained from Clontech (Palo Alto, CA), and anti-rabbit
secondary antibody was from Santa Cruz Biotechnology (Santa Cruz,
CA). The Vybrant apoptosis assay kit was purchased from Molecular
Probes, Inc. (Eugene, OR), and TransFast transfection reagent and the
antibiotic G418 were from Promega (Madison, WI). Other substrates,
enzymes, and coenzymes were purchased from Sigma, Roche Diagnos-
tics, or Merck (Darmstadt, Germany).
Cell Cultures
Astrocyte-rich primary cultures derived from neonatal 1-day-old
Wistar rats were prepared as previously described (28). Cell suspen-
sions were plated in culture medium supplemented with 10% (v/v) fetal
calf serum at a density of 1.25  105 cells/cm2 in 175-cm2 flasks. Cells
were maintained in a humidified incubator under an atmosphere of 5%
CO2 and 95% air at 37 °C with a change of medium twice a week. After
12–14 days, cells were collected by trypsinization and reseeded in
culture medium at a density of 2.5  105 cells/cm2 on appropriate
plastic dishes. For the experiments, astrocytes were used 24 h after
reseeding.
Cerebral cortex neurons in primary culture were prepared from fetal
rats at 16–17 days of gestation (29). Dissociated cell suspensions were
plated at a density of 2.5  105 cells/cm2 on appropriate plastic dishes
previously coated with poly-D-lysine (15 g/ml) in culture medium sup-
plemented with 10% fetal calf serum. Cells were incubated at 37 °C in
a humidified atmosphere containing 5% CO2 and 95% air. Forty-eight
hours after plating, the culture medium was replaced with DMEM
supplemented with 5% horse serum and 20 mM D-glucose. On day 4 of
culture, cytosine arabinoside was added (10 M) to prevent non-neuro-
nal proliferation. For the experiments, neurons were used on day 9.
PC12 cells were kindly provided by Dr. Dionisio Martı´n-Zanca (Uni-
versidad de Salamanca, Salamanca, Spain) and were maintained in
DMEM supplemented with 10% fetal calf serum, 6% horse serum, and
20 mM glucose on collagen-coated plastic dishes. For selection and
growth of stably transfected cells, this medium was supplemented with
G418 (500 g/ml).
G6PD Plasmid Constructs and PC12 Stable Transfection
Full-length rat G6PD cDNA was subcloned into the EcoRI site of the
mammalian expression vector pEGFP (Clontech) and sequenced. Con-
structs with the G6PD gene inserted in the sense (pEGFP-G6PD-sense)
or antisense (pEGFP-G6PD-antisense) orientation were selected. PC12
cells were seeded at a density of 1  105 cells/cm2 and transfected by
lipofection (TransFast) with pEGFP-G6PD-sense, pEGFP-G6PD-anti-
sense, or pEGFP plasmid constructs following the manufacturer’s in-
structions. Forty-eight hours after transfection, cells were passaged and
incubated in culture medium containing G418 (500 g/ml), with a
medium change twice a week to allow the selection of stably expressing
clones. Isolated colonies were transferred to 12-well plates and ex-
panded. Different clones were subjected to Northern blotting for G6PD
mRNA identification as well as G6PD activity determination. Clones
showing maximum (sense) or minimum (antisense) G6PD activities
were used for the experiments.
Measurement of Glucose Oxidation through the Pentose
Phosphate Pathway
The activity of the PPP was measured essentially as described by
Hothersall et al. (30) based on the determination of the difference in
14CO2 production from [1-
14C]glucose (decarboxylated by the 6-phos-
phogluconate dehydrogenase-catalyzed reaction and by the Krebs cycle)
and from [6-14C]glucose (decarboxylated only by the Krebs cycle). As-
trocytes and neurons grown in 175-cm2 flasks were collected by
trypsinization. Cell pellets were resuspended in O2-saturated incuba-
tion buffer (11 mM sodium phosphate, 122 mM NaCl, 3.1 mM KCl, 0.4
mM KH2PO4, 1.2 mM MgSO4, and 1.3 mM CaCl2, pH 7.4). Aliquots (500
l) of the suspension were placed in Erlenmeyer flasks containing 2 Ci
of D-[1-14C]glucose or 8 Ci of D-[6-14C]glucose (5.5 mM D-glucose) in
either the absence (control) or presence of SIN-1 at the indicated con-
centrations. Each Erlenmeyer flask was equipped with a central well
containing an Eppendorf tube containing benzethonium hydroxide. The
flask atmosphere was flushed with O2 for 20 s, after which the flask was
sealed with a rubber cap and incubated for 5 min at 37 °C in a water
bath with shaking. Incubations were stopped by injection into the main
well of 0.2 ml of 1.75 M HClO4, although shaking was continued for a
further 20 min to facilitate the entrapment of 14CO2 by benzethonium
hydroxide. The radioactivity trapped by benzethonium hydroxide was
measured in scintillation fluid (Universol, ICN Biomedicals Inc., Irvine,
CA) by liquid scintillation counting (98% efficiency; LS 6500, Beckman
Instruments). Blanks without cells were used in parallel to measure
background radioactivity, which was subtracted from the sample val-
ues. Preliminary experiments showed that, under these conditions, the
14CO2 generated was linear with time, at least up to 30 min, in both
control and SIN-1 (up to 1 mM)-treated cells. Protein contents were
determined in 10-l aliquots of the cell suspensions. For the calcula-
tions, the specific radioactivity (dpm/mol) of glucose was used, and the
results are expressed as pmol of glucose transformed into CO2/min/mg
of protein.
Metabolite Determinations
Total and Oxidized Glutathione—For glutathione determinations,
cells grown in 8-cm2 wells were washed with ice-cold phosphate-buff-
ered saline (PBS) and immediately collected by scraping off with 1%
(w/v) sulfosalicylic acid. Cell lysates were centrifuged at 13,000  g for
5 min at 4 °C, and the supernatants were used for glutathione deter-
minations on the same day as previously described (25, 31, 32). Total
glutathione contents (GSx) were determined in comparison with GSSG
standards (0–50 M) treated in the same way as the samples. GSSG
was quantified after derivatization of GSH with 2-vinylpyridine using
similarly treated GSSG standards (0–5 M). Results are expressed as
the oxidized glutathione status ((GSSG/GSx)  100) (33).
Nicotinamide-adenine Dinucleotides—Cells seeded on 4-cm2 plates
were washed with ice-cold PBS, and 250 l of 0.5 M KOH in 50% (v/v)
ethanol was immediately added, as described by Stocchi et al. (34) for
the stable extraction of both reduced and oxidized nicotinamide-ade-
nine dinucleotides. Aliquots (200 l) of the cell lysates were transferred
to Eppendorf tubes, neutralized to a pH of 7.8 with 200 l of 0.5 M
triethanolamine and 0.5 M potassium phosphate, and centrifuged at
13,000 g for 2 min at 4 °C. Fifty-microliter aliquots of the supernatant
were immediately used for NADPH plus NADH determination by
chemiluminescence as previously described (35). For NADPH determi-
nations, NADH was previously oxidized by incubating the samples with
0.5 milliunits/l lactate dehydrogenase and 1 mM pyruvate (36). For
NADP determinations, NADP was previously reduced by incubating
the samples with 5 milliunits/ml G6PD, 5 mM glucose 6-phosphate, and
5 mM MgSO4 (36). For NAD
 determinations, NAD was previously
reduced by incubating the samples with 5 milliunits/l alcohol dehy-
drogenase and 172 mM ethanol (36). NADPH, NADH, NADP, and
NAD concentrations were calculated by extrapolation of the sample
values to their respective appropriate standard curves obtained with
pure standards (Sigma).
Glucose 6-Phosphate and 6-Phosphogluconate—Cells were washed
with ice-cold PBS and deproteinized with 0.6 M HClO4. Cells were
scraped off the plastic dishes and centrifuged at 20,000  g for 10 min
at 4 °C. After neutralization of the supernatants with 5 M K2CO3, the
neutralized extracts were lyophilized and resuspended in 250 l of
water. Glucose 6-phosphate (37) and 6-phosphogluconate (38) concen-
trations were determined in these samples as described.
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G6PD Activity Determinations
Cells were resuspended in 500 l of 0.1 M potassium phosphate
buffer, pH 7.0, to give a final protein concentration of 1 mg/ml and
homogenized with a Ultraturrax T-8 homogenizer (Ika, Staufen, Ger-
many), and G6PD activity was determined spectrophotometrically as
previously described (39). Enzyme activity is expressed as nmol of
glucose 6-phosphate transformed per min/mg of protein.
Northern Blotting
Northern blot analysis was carried out on total RNA samples isolated
from the cells by the guanidinium isothiocyanate method as previously
described (40). The samples were electrophoresed (15 g of RNA/line)
on a formaldehyde-containing 1% (w/v) agarose gel. After transfer to a
GeneScreen Plus membrane (PerkinElmer Life Sciences) and cross-
linking with ultraviolet irradiation (UV Stratalinker Model 2400, Ge-
netic Research Instruments, Essex, UK), membranes were hybridized
for 18 h at 65 °C in the presence of the appropriate random-primed
[-32P]dCTP-radiolabeled cDNA probes and exposed to Eastman Kodak
XAR-5 film. As cDNA probes, we used either the 2.2-kb cDNA encoding
the full-length rat G6PD gene (a generous gift from Dr. Ye-Shih Ho,
Wayne State University) or a 0.7-kb cDNA fragment of the rat cyclo-
philin gene (generously donated by Dr. Dionisio Martı´n-Zanca). Cyclo-
philin mRNA was used as a control of the amount of total RNA loaded
in each lane.
Western Blotting
Cells were scraped off the plastic dishes with lysis buffer (12.5 mM
Na2HPO4, 116 mM NaCl, 0.5 M EDTA, 1% (v/v) Triton X-100, 0.1% (w/v)
SDS, 100 M N-p-tosyl-L-lysine chloromethyl ketone, 100 M phenyl-
methylsulfonyl fluoride, 1 mM phenanthroline, 10 g/ml pepstatin A,
100 M N-tosyl-L-phenylalanine chloromethyl ketone, 10 g/ml leupep-
tin, 10 g/ml aprotinin, and 10 g/ml soybean trypsin inhibitor, pH 7),
and aliquots containing 100 g of protein from each sample, extempo-
rarily determined following the method of Bradford (41) using ovalbu-
min as a standard and the BenchMarkTM prestained protein ladder
(Invitrogen), were electrophoresed on 10% acrylamide gel (MiniPro-
tean®, Bio-Rad) and transferred to a Hybond® nitrocellulose membrane.
Membranes were blocked with 5% (w/v) low-fat milk/TBST buffer (20
mM Tris, 500 mM NaCl, and 0.1% (w/v) Tween 20, pH 7.5) for 1 h and
then incubated in the presence of the appropriate antibody (either
anti-G6PD at 1:1000 dilution or anti-GFP at 1:250 dilution) at 4 °C
overnight. After washing, membranes were further incubated in 3%
(w/v) low-fat milk/TBST buffer for 45 min at room temperature in the
presence of horseradish peroxidase-conjugated anti-rabbit IgG second-
ary antibody at 1:40,000 dilution and immediately incubated with the
luminol chemiluminescence reagent (Santa Cruz Biotechnology) for 1
min before being exposed to HyperfilmTM chemiluminescence film for 3
min (anti-G6PD antibody) or 25 min (anti-GFP antibody).
G6PD Release Experiments
Astrocytes or neurons were removed from the flasks by mild
trypsinization and resuspended at a density of 20  106 cells/ml in
prewarmed (37 °C) buffered Hanks’ solution (5.26 mM KCl, 0.43 mM
KH2PO4, 132.4 mM NaCl, 4.09 mM NaHCO3, 0.33 mM Na2HPO4, 20 mM
glucose, 2 mM CaCl2, and 20 mM HEPES, pH 7.4) containing streptol-
ysin O (1 kilounit/ml) (42) and the protease inhibitor mixture (see
above). Cells were incubated in either the absence (control) or presence
of SIN-1 (1 mM) at 37 °C in a water bath with shaking for 30 min
(astrocytes) or 5 min (neurons). When appropriate, some incubations
were performed in the presence of a degraded SIN-1 solution (72 h at
37 °C). After the incubation period, aliquots of the cell suspension were
centrifuged at 500  g, and both the supernatants and pellets were
subjected to anti-G6PD antibody Western blotting as described above.
Films were scanned; the intensity of the bands was quantified; and the
values were subtracted from the background intensity values using an
image analyzer system (NIH Image), kindly supplied by Wayne Ras-
band (National Institutes of Health).
Formation of Endogenous Peroxynitrite
To estimate the endogenous formation of peroxynitrite from astro-
cytes (43), cells were treated with LPS (1 g/ml) for 18 h in either the
absence or presence of the peroxynitrite scavenger methionine (10 mM)
(44). Peroxynitrite generation was shown by the ability of these cells to
oxidize dihydrorhodamine 123 as previously described (45). Thus, cells
were incubated with dihydrorhodamine 123 (1 g/ml) in buffered
Hanks’ solution for 1 h at 37 °C, and rhodamine 123 fluorescence
microphotographs were taken with an inverted microscope using a
fluorescein filter (excitation filter, 480–490 nm; and emission filter,
510–560 nm).
Flow Cytometric Analysis of Apoptosis
Early apoptotic cell death was determined after staining with Alexa
Fluor 488-conjugated annexin V and propidium iodide using a commer-
cially available kit (Molecular Probes, Inc.) following the manufactur-
er’s instructions. Data acquisition (10,000 cells) was carried out in a
FACSCalibur flow cytometer (BD Biosciences) equipped with a 15-
milliwatt argon ion laser tuned at 488 nm using CellQuest software (BD
Biosciences). The analyzer threshold was adjusted on the FSC channel
to exclude noise and most of the subcellular debris. Annexin V-stained
cells that were propidium iodide-negative (annexin V/propidium io-
dide) were considered to be apoptotic.
Protein Determinations
Proteins were determined in the cell lysates by the method of Lowry
et al. (46) or Bradford (41) using bovine serum albumin as a standard.
Statistical Analysis
Results are expressed as the means  S.E. for the number of culture
preparations indicated in the figure legends. Statistical significance
was evaluated by one-way analysis, followed by the least significant
difference multiple range test. In all cases, p  0.05 was considered
significant.
RESULTS
Peroxynitrite Triggers a Rapid and Persistent Increase in
PPP Activity and NADPH Concentrations in Astrocytes and
Neurons—To address the potential involvement of peroxyni-
trite in the regulation of PPP activity, the differences in the
rates of oxidation of D-[1-14C]glucose and D-[6-14C]glucose to
14CO2 (30) during a 5-min incubation period were assessed in
astrocytes and neurons in primary culture. Because of the
extreme instability of authentic peroxynitrite solutions at
physiological pH (half-life of 1.7 s), we used SIN-1 as the
peroxynitrite donor (47, 48). Preliminary experiments using
the NO-sensitive electrode (ISO-NO) (data not shown) sug-
gested an approximate peroxynitrite formation from SIN-1 (1
mM) of 20 M, as previously reported (48). To ensure imme-
diate maximum peroxynitrite release from SIN-1, all SIN-1-
containing solutions were always preincubated in DMEM at
37 °C for 20 min before addition to the cells. As shown in Fig.
1A, the PPP activity found in control astrocytes was 2.6-fold
higher than that found in control neurons. Incubation of both
cell types with SIN-1 dose-dependently increased the PPP ac-
tivity to values ranging between 2- or 1.5-fold at 0.25 mM
SIN-1 and up to 3.5- or 2.5-fold at 1 mM SIN-1 in astrocytes
or neurons, respectively (Fig. 1A). In all cases, the observed
enhancement of PPP activity by peroxynitrite treatment was
due to increased [1-14C]glucose oxidation, whereas [6-14C]glu-
cose oxidation remained unaltered (data not shown).
To investigate whether the observed activation of PPP activ-
ity by peroxynitrite was associated with NADPH generation,
the intracellular concentrations of this dinucleotide were as-
sessed by chemiluminescence after exposure of the cells to
SIN-1. As shown in Fig. 1B, NADPH concentrations were 4-
fold higher in control astrocytes than in control neurons. Incu-
bation of the cells with SIN-1 for 10 min dose-dependently
increased NADPH concentrations by 1.8- and 4.4-fold at 1
mM SIN-1 in astrocytes and neurons, respectively (Fig. 1B). To
test whether peroxynitrite was the molecule responsible for the
observed SIN-1-mediated increase in NADPH concentrations, a
solution of SIN-1 (1 mM) was preincubated in DMEM at 37 °C
for 72 h to ensure complete degradation of SIN-1 before addi-
tion to neurons. Under these conditions, incubation of the neu-
rons at 37 °C for 5 min with degraded solutions of SIN-1
showed no effects on NADPH levels compared with control
(untreated) cells, whereas “active” SIN-1 triggered an 4-fold
increase (Fig. 1C). To further confirm that peroxynitrite forma-
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tion from SIN-1 was responsible for the observed effects on
NADPH concentrations, we used TEMPOL (500 mM) or hemo-
globin (50 M) to scavenge O2
. (49) or NO (2), respectively. As
shown in Fig. 1C, the presence of either compound fully pre-
vented SIN-1 (1 mM)-mediated increases in neuronal NADPH
concentrations. These results contrast with those obtained by
Kirsch and de Groot (44), who found peroxynitrite reaction with
reduced nicotinamide nucleotides in vitro. Even though we
have no explanation for this discrepancy, it may be possible
that such a putative reaction (44) would be interfered with by
the presence of unknown factors occurring in our biological
systems.
Measurements of NADPH levels for short incubation periods
revealed that the increase in the concentrations of this dinu-
cleotide by SIN-1 was very rapid (within 1 min) in both cell
types (Fig. 1D). Furthermore, incubation of the cells in the
presence of SIN-1 for longer times revealed that the increase in
NADPH concentrations observed at 10 min was transient in
astrocytes, but not in neurons (Fig. 1, B–D). Thus, after 30 min
of incubation, the SIN-1-mediated rise in NADPH concentra-
tions was progressively attenuated, with a modest, although
statistically significant, 1.2-fold value being reached at 24 h
(Fig. 1E). In contrast to astrocytes, neuronal NADPH concen-
trations progressively increased after the first minute of incu-
bation with SIN-1, reaching up to 5.2-fold at 30 min and
11-fold at 4 h of incubation (Fig. 1F). Furthermore, neuronal
NADPH concentrations were maintained at high levels along
during the incubation time in the presence of SIN-1, for at least
up to 24 h (Fig. 1F).
Peroxynitrite Triggers Activation of the G6PD-catalyzed Re-
action—To investigate the mechanism through which per-
oxynitrite triggered the rapid activation of PPP activity and
NADPH concentrations, we determined the levels of nicotin-
amide-adenine dinucleotides in peroxynitrite-treated astro-
cytes. As shown in Fig. 2A, the increase in NADPH concentra-
tions observed after 30 min of incubation with SIN-1 (1 mM)
was accompanied by a parallel decrease in NADP levels, sug-
gesting that at least some of the NADPH produced would be
obtained from NADP reduction. However, the decreased
amount of NADP (50 pmol/mg of protein) per se could not
account for the increased amount of NADPH (130 pmol/mg of
protein) (Fig. 2A). NAD concentrations were noticeably de-
creased by 100 pmol/mg of protein, and NADH levels by 40
pmol/mg of protein following peroxynitrite treatment (Fig. 2A).
Furthermore, SIN-1 treatment (1 mM, 30 min) elicited a de-
crease in glucose 6-phosphate concentrations (by 40%) and an
increase in 6-phosphogluconate concentrations (by 5-fold)
(Fig. 2B), strongly suggesting that peroxynitrite activates the
G6PD-catalyzed reaction, i.e. the first rate-limiting step in the
PPP (22). To investigate the possible activation of G6PD by
FIG. 1. Peroxynitrite triggers a
rapid and persistent increase in PPP
activity and NADPH concentrations
in astrocytes and neurons. A, for the
measurement of PPP activity, cell suspen-
sions (15  106 cells/ml) were incubated
in the presence of appropriate concentra-
tions of SIN-1 in O2-saturated incubation
buffer, pH 7.4, containing either 2 Ci of
D-[1-14C]glucose or 8 Ci of D-[6-14C]glu-
cose (5.5 mM D-glucose) at 37 °C for 5 min.
The 14CO2 released by the cells was
trapped and quantified for the estimation
of PPP activity as described under “Ex-
perimental Procedures.” B–F, for the de-
termination of NADPH concentrations,
cells were incubated in DMEM in the ab-
sence (control) or presence of SIN-1 at the
indicated concentrations and with TEM-
POL or hemoglobin when appropriate (C)
for 1 min to 24 h (10 min in B and 5 min
in C) and digested in KOH/ethanol for
NADPH determination by chemilumines-
cence as described under “Experimental
Procedures.” Data are the means  S.E.
obtained from three to four different ex-
periments. *, p  0.05 compared with the
corresponding control (0 mM SIN-1) val-
ues; #, p  0.05 compared with the corre-
sponding values found in neurons.
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peroxynitrite directly, the activity of G6PD was determined
spectrophotometrically in the homogenates obtained from con-
trol (untreated) or SIN-1-treated astrocytes. The results
showed that, despite the biochemical evidence for G6PD acti-
vation (Fig. 2B), total G6PD was unmodified by peroxynitrite
treatment (Fig. 2C). In this context, previous observations by
Stanton et al. (42) have demonstrated that inactive, structural
intracellular element-bound G6PD would be prone to rapid
activation through the release of G6PD into the cytosolic frac-
tion by treatment of renal cortical cells with growth factors.
Accordingly, we decided to investigate whether peroxynitrite-
mediated G6PD activation could be due to possible enzyme
release. Thus, astrocytes were collected, and the cell suspen-
sion was permeabilized by mild treatment with streptolysin O
(42) and exposed or not (control) to active SIN-1 (1 mM) or
degraded SIN-1. After 30 min, the cell suspensions were cen-
trifuged, and both the cytosolic supernatants and pellets were
separately subjected to Western blotting using anti-G6PD an-
tibody. The results showed that, whereas most of the G6PD
remained in the pellets, a significant amount of it appeared in
the supernatant of SIN-1-treated cells compared with control
or degraded SIN-1-treated cells (band intensity in the super-
natants, 16.6  0.2 and 36.6  0.1 arbitrary units for degraded
SIN-1 and SIN-1, respectively) (Fig. 2D). These results suggest
that peroxynitrite would activate G6PD activity by promoting
the release of G6PD to the cytosol from a structural intracel-
lular element.
Evidence for Activation of the G6PD-catalyzed Reaction by
Endogenous Peroxynitrite in Astrocytes—To assess whether en-
dogenous peroxynitrite promoted G6PD activation, astrocytes
were incubated with LPS (1 g/ml) for 18 h as previously
reported (43). Endogenous peroxynitrite production was evi-
denced by the ability of LPS-treated cells to oxidize dihydror-
hodamine 123 to rhodamine 123 (45). Thus, LPS increased
rhodamine 123 fluorescence, an effect that was prevented by
co-incubation with the peroxynitrite scavenger methionine (10
mM) (Fig. 3A) (44). As shown in Fig. 3B, LPS elicited a decrease
in glucose 6-phosphate concentrations (by 3-fold) and an in-
crease in 6-phosphogluconate concentrations (by 2.5-fold),
strongly suggesting G6PD activation. Furthermore, these ef-
fects were counteracted by scavenging peroxynitrite with me-
thionine (Fig. 3B).
Evidence for G6PD Activation by Peroxynitrite in Neu-
rons—To further confirm that peroxynitrite was responsible for
the increase in neuronal NADPH concentrations, we used a
solution of authentic peroxynitrite (ONOO, stock alkaline
solutions of 0.5 M, synthesized in our laboratory). Due to its
extreme instability (half-life of 1.7 s at pH 7.4), neurons were
exposed to repeated pulses (10 pulses, one pulse every 30 s) of
peroxynitrite (final concentrations of 50 and 100 M) during the
5-min incubation period. Under these conditions, our results
showed that exposure of neurons to authentic peroxynitrite
increased NADPH concentrations by 1.8-fold (50 M ONOO)
or 4-fold (100 M ONOO) (Fig. 4), whereas a degraded
ONOO solution (1 mM, 30 min, 37 °C) had no effect on
NADPH concentrations (Fig. 4A). To investigate whether the
peroxynitrite-mediated G6PD enzyme release observed in as-
trocytes also occurred in neurons, these cells were collected,
and the cell suspension was exposed to active SIN-1 (1 mM) or
degraded SIN-1. After 5 min, the cell suspensions were centri-
fuged, and the cytosolic supernatants were subjected to West-
ern blotting using anti-G6PD antibody. The results showed a
significant increase in G6PD protein in the supernatant of
SIN-1-treated neurons compared with degraded SIN-1-treated
cells (band intensity in the supernatants, 20.8 0.1 and 32.6
0.1 arbitrary units for degraded SIN-1 and SIN-1, respectively)
(Fig. 4B).
Overexpression of the G6PD Gene Increases and Inhibition of
G6PD Gene Expression Decreases NADPH Concentrations in
PC12 Cells—To assess the essential role played by G6PD ac-
tivity in generating intracellular NADPH, we used a transgene
approach to endogenously modulate G6PD gene expression.
Thus, we obtained stable G6PD gene-expressing cells by trans-
fecting PC12 cells with pEGFP mammalian plasmid vectors
into which the full-length G6PD gene had been inserted in
either the sense (PC12-pEGFP-G6PD-sense) or antisense
(PC12-pEGFP-G6PD-antisense) orientation. Transfection of
PC12 cells with the vector alone (PC12-pEGFP) was also car-
FIG. 2. Peroxynitrite triggers acti-
vation of the G6PD-catalyzed reac-
tion. Astrocytes were incubated at 37 °C
for 30 min in either the absence (control)
or presence of SIN-1 (1 mM) as well as,
where indicated, a degraded solution of
SIN-1. A, for the determination of NAD
concentrations, cells were digested in
KOH/ethanol and used for the NADPH,
NADH, NADP, and NAD chemilu-
minescence assays as described under
“Experimental Procedures.” B, glucose
6-phosphate and 6-phosphogluconate con-
centrations were determined in the neu-
tralized perchloric acid cell extracts. C,
G6PD activity was determined spectro-
photometrically in the cell homogenates.
D, for the assessment of G6PD release,
cell suspensions (20  106 cells/ml) were
incubated in Hanks’ solution containing
streptolysin O (1 kilounit/ml) plus SIN-1
(1 mM) at 37 °C for 30 min, and aliquots of
these suspensions were centrifuged be-
fore anti-G6PD antibody Western blot
analyses of both the supernatant and pel-
lets. Data are the means  S.E. obtained
from three different experiments. *, p 
0.05 compared with the corresponding
control values.
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ried out as a control. Stably expressing cells were selected and
analyzed for G6PD mRNA levels, G6PD-GFP fusion protein
levels, G6PD activity, and intracellular NADPH concentra-
tions. Northern blot analyses showed that control cells (un-
transfected PC12 and transfected PC12-pEGFP) expressed en-
dogenous G6PD mRNA (Fig. 5A). Furthermore, Western blot
analyses using anti-GFP antibody revealed an 27-kDa band
in PC12-pEGFP cells that was not present in PC12 cells, con-
firming successful expression of the GFP protein in the former
cells (Fig. 5A). Northern blot analyses of sense G6PD gene-
overexpressing cells (PC12-pEGFP-G6PD-sense) revealed an
additional mRNA band corresponding to the G6PD-GFP
mRNA transcript (Fig. 5A). Western blot analyses of PC12-
pEGFP-G6PD-sense cell protein extracts using anti-GFP anti-
body disclosed an 86-kDa band, confirming successful expres-
FIG. 3. Evidence for activation of
the G6PD-catalyzed reaction by en-
dogenous peroxynitrite in astro-
cytes. Astrocytes were incubated at 37 °C
for 18.5 h in either the absence (control)
or presence of LPS (1 g/ml) alone or in
combination with methionine (10 mM).
A, dihydrorhodamine 123 oxidation was
examined by fluorescence microscopy as
indicated under “Experimental Proce-
dures.” B, glucose 6-phosphate and
6-phosphogluconate concentrations were
determined in the neutralized perchloric
acid cell extracts. Data are the means 
S.E. obtained from three different exper-
iments. *, p  0.05 compared with the
corresponding control values.
FIG. 4. Evidence for G6PD activation by peroxynitrite in neu-
rons. A, neurons were incubated for 5 min in the presence of peroxyni-
trite, which was added to the cells in 10 pulses (one pulse every 30 s) of
either 50 or 100 M (final concentration, in Hanks’ solution) from a 0.5
M stock solution. Cells were digested in KOH/ethanol for NADPH de-
termination by chemiluminescence as described under “Experimental
Procedures.” B, for the assessment of G6PD release, cell suspensions
(20  106 cells/ml) were incubated in Hanks’ solution containing SIN-1
(1 mM) at 37 °C for 5 min, and aliquots of these suspensions were
centrifuged before anti-G6PD antibody Western blot analyses of the
supernatant. Data are the means  S.E. obtained from three to four
different experiments. *, p  0.05 compared with control or degraded
ONOO values.
FIG. 5. Overexpression of G6PD increases and inhibition of
G6PD expression decreases NADPH concentrations in PC12
cells. Cells were stably transfected with pEGFP plasmid vectors into
which the G6PD gene had been inserted in either the sense (PC12-
pEGFP-G6PD-sense) or antisense (PC12-pEGFP-G6PD-antisense) ori-
entation. As transfection controls, cells were also transfected with
pEGFP alone (PC12-pEGFP). A, total RNA and protein samples were
extracted from these clones and subjected to Northern (15 g/lane using
either a G6PD or cyclophilin cDNA probe) and Western (100 g/lane
using anti-GFP antibody) blot analyses, respectively. B, G6PD activity
and NADPH concentrations were determined in either cell homoge-
nates (in 0.1 M phosphate buffer, pH 7.0) or alkaline extracts (KOH/
ethanol), respectively, as described under “Experimental Procedures.”
*, p  0.05 compared with the corresponding PC12 and PC12-pEGFP
values.
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sion of the G6PD-GFP fusion protein (Fig. 5A). Analysis of
these protein extracts by Western blotting failed to detect any
anti-G6PD immunopositive fusion band, probably due to the
interference of the fused GFP moiety in antibody recognition.
Northern and Western blot analyses of antisense G6PD gene-
overexpressing cells (PC12-pEGFP-G6PD-antisense) revealed
a weak G6PD-GFP mRNA band and undetectable GFP or
G6PD-GFP protein (Fig. 5A), probably due to the increased
degradation of newly synthesized G6PD mRNA, as judged by
the proposed mechanism for antisense gene-silencing methods
(50, 51). Interestingly, both G6PD activity and NADPH con-
centrations were significantly higher (1.5-fold) in PC12-
pEGFP-G6PD-sense cells compared with control (untrans-
fected) and pEGFP-transfected cells (Fig. 5B). In contrast,
G6PD activity and NADPH concentrations in PC12-pEGFP-
G6PD-antisense cells were significantly lower (by 24%) (Fig.
5B). These results strongly confirm the functional efficiency of
G6PD transgene expression in these cells and point to the
essential role played by G6PD activity in supporting an en-
hanced intracellular pool of NADPH.
Peroxynitrite Transiently Prevents Nitric Oxide-mediated
Neuronal NADPH Depletion, Glutathione Oxidation, and Apo-
ptosis—Previous results from our laboratory (52) demonstrated
that the exposure of neurons to NO causes apoptosis, whereas
astrocytes remain unaffected. Among other possible mecha-
nisms, this differential intercellular susceptibility appears to
involve the higher antioxidant reserve, such as glutathione
concentrations, found in astrocytes compared with neurons (17,
53). We were therefore prompted to investigate whether the
peroxynitrite-mediated activation of PPP activity and in-
creased NADPH concentrations observed here might serve as a
potential neuroprotective mechanism against NO-mediated
glutathione oxidation and cytotoxicity. Astrocytes and neurons
were incubated in the presence of the NO donor DETA-NO (1
mM), a compound widely used as a long-term chemical source of
NO (54). DETA-NO (1 mM) was seen to continuously release
2.8 M NO for 24 h in DMEM at 37 °C as measured by an
NO-sensitive electrode. To ensure immediate maximum NO
release from DETA-NO, all DETA-NO-containing solutions
were always preincubated in DMEM at 37 °C for 20 min before
addition to the cells. Exposure of astrocytes to NO for 4 h had
no detectable effect on NADPH concentrations, the GSSG/GSx
ratio, or apoptotic cell death (Table I). In contrast to astrocytes,
neurons were highly susceptible. Thus, exposure of neurons to
NO triggered an 50% decrease in NADPH concentrations, a
2-fold increase in the GSSG/GSx ratio, and a 1.7-fold increase
in the proportion of apoptotic cells (Table I). Neuronal NADPH
depletion by DETA-NO (1 mM) treatment occurred very
rapidly, as judged by the 30% decrease in NADPH concentra-
tions observed after a 5-min incubation period (Table II). Fur-
thermore, a solution of degraded DETA-NO (incubation of 1 mM
DETA-NO in DMEM at 37 °C for 48 h) had no effect, and a
bolus of authentic NO (10 M) decreased NADPH concen-
trations in neurons by 23% after a 5-min incubation period
(Table II).
We next investigated whether the stimulation of PPP activ-
ity brought about by peroxynitrite might protect neurons
against NO-mediated oxidative damage. To perform these ex-
periments, neurons were incubated under four different condi-
tions, (a) control (untreated) neurons incubated in DMEM for
9 h; (b) neurons preincubated with SIN-1 for 1 h, followed by
washing with PBS, and then incubated in DMEM for a further
8 h; (c) neurons incubated with DETA-NO for 8 h; and (d)
neurons preincubated with SIN-1 for 1 h, followed by washing
with PBS, and incubated with DETA-NO for a further 8 h. As
shown in Fig. 4A, incubation of neurons with DETA-NO mark-
edly and persistently decreased neuronal NADPH concentra-
tions over the 8-h incubation period. By contrast, treatment of
neurons with SIN-1 for 1 h increased NADPH concentrations
(Fig. 6A; see also Fig. 1F). This effect was transient, as judged
by the observed progressive decrease in the concentrations of
this dinucleotide after SIN-1 removal. Noticeably, despite this
progressive decrease, NADPH concentrations remained at lev-
els that were significantly higher than those observed in con-
trol neurons, at least up to the end of the 8-h incubation period
(Fig. 6A). Interestingly, preincubation of neurons with SIN-1
for 1 h fully or partially prevented the DETA-NO-mediated
decrease in NADPH concentrations, at least during the follow-
ing 8-h incubation period (Fig. 6A).
To assess the glutathione redox status in neurons subjected
to an identical treatment, we determined oxidized (GSSG) and
total (GSx) glutathione concentrations in these cells, express-
ing the values as the GSSG/GSx ratio (oxidized glutathione
status) (33). As shown in Fig. 6B, the neuronal oxidized gluta-
thione status remained unaltered over the 8-h incubation pe-
riod following SIN-1 pretreatment, although it increased after
24 h (control, 5.2  0.5; and SIN-1, 4.8  0.2; n  3). SIN-1
pretreatment noticeably prevented the long-term oxidation (8
h) of glutathione observed in control cells. In contrast to SIN-1,
the exposure of neurons to DETA-NO significantly increased
the oxidized glutathione status from 1 h up to 8 h of incubation
(Fig. 6B). Also, pretreatment of neurons with SIN-1 for 1 h
partially prevented DETA-NO-mediated glutathione oxidation
during the incubation period between 1 and 4 h, but failed to
protect glutathione oxidation after 8 h (Fig. 6B). It should be
mentioned that the changes in the GSSG/GSx ratio observed
TABLE II
Rapid NADPH depletion by nitric oxide in neurons in primary culture
Neurons were incubated in the absence (control) or presence of either
degraded DETA-NO (48 h at 37 °C) or active DETA-NO (1 mM; 2.8 M




Control 126  5
Degraded DETA-NO (1 mM) 126  2
DETA-NO (1 mM) 89  11a
Nitric oxide (10 M) 97  7a
a p  0.05 compared with control or degraded DETA-NO values.
TABLE I
Effect of nitric oxide on NADPH levels, oxidized glutathione status, and apoptotic cell death in astrocytes and neurons in primary culture
Cells were incubated in the absence (control) or presence of DETA-NO (1 mM; 2.8 M NO) for 4 h, and NADPH concentrations, total (GSx)
and oxidized (GSSG) glutathione concentrations, and apopototic cell death were evaluated as described under “Experimental Procedures.”
PI, propidium iodide.
Astrocytes Neurons
Control DETA-NO Control DETA-NO
NADPH (pmol/mg protein) 290  11 279  10 121  9 59  3a
(GSSG/GSx)  100 0.61  0.05 0.41  0.03 2.48  0.21 4.15  0.19a
Apoptotic cells (% annexin V/PI) 2.30  0.01 2.89  0.02 19.31  0.85 33.7  1.60a
a p  0.05 compared with the corresponding control values.
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were due to changes in GSSG (not GSx) concentrations (values
for control (2 h), SIN-1 (1 h) plus none (1 h), DETA-NO (1 h),
and SIN-1 (1 h) plus DETA-NO (1 h) were 0.30  0.03, 0.30 
0.02, 0.45  0.02 (p  0.05 versus control), and 0.34  0.02
nmol/mg of protein for GSSG and 13.1  0.6, 12.9  0.3, 12.9 
0.6, and 13.1  1.0 nmol/mg of protein for GSx, respectively).
To investigate whether the peroxynitrite-mediated protec-
tion of cellular oxidation dictated cellular survival, we deter-
mined the proportion of apoptotic cells, i.e. propidium iodide-
negative neurons showing a positive immunoreaction to
annexin V (% of annexin V/propidium iodide cells), by flow
cytometry. As shown in Fig. 6C, preincubation of neurons with
SIN-1 for 1 h had no effect on the proportion of apoptotic
neurons compared with control cells, at least up to 8 h of
incubation. In contrast, incubation of neurons with DETA-NO
triggered cellular apoptosis in a time-dependent fashion (Fig.
6C). However, a 1-h pretreatment of neurons with SIN-1 fully
(1 h) or partially (4–8 h) prevented DETA-NO-mediated neu-
rotoxicity (Fig. 6C). Because a considerable body of earlier work
(e.g. Refs. 8, 9, and 17) has consistently reported the long-term
neurotoxicity (24 h) of peroxynitrite, we also investigated this
possibility. Indeed, both a 1-h pretreatment of neurons with
SIN-1 (1 mM), followed by a 23-h incubation in DMEM, and a
continuous exposure (24 h) of neurons to SIN-1 (1 mM) signif-
icantly increased apoptotic cell death (control at 24 h, 19.0 
0.6%; a 1-h incubation with SIN-1, followed by a 23-h incuba-
tion in DMEM, 50.6  5.1%; and a 24-h incubation with SIN-1,
57.6  0.7%). Finally, to further confirm that ONOO was the
species responsible for the protection shown by the neurons
against NO-mediated apoptosis, the cells were treated with
ONOO (10 pulses of 50 M ONOO for 5 min) before exposure
to DETA-NO (1 mM, 30 min). As shown in Table III, the 1.4-
fold increase in apoptotic neurons observed after 30 min of
incubation with DETA-NO was prevented by pretreatment
with ONOO.
Overexpression of the G6PD Gene Protects and Inhibition of
G6PD Gene Expression Enhances Nitric Oxide-mediated Apo-
ptotic Death in PC12 Cells—In view of the biochemical evidence
suggesting a key role for G6PD activity in peroxynitrite-medi-
ated protection against NO, we investigated whether the en-
dogenous modulation of G6PD transgene expression might be
responsible for NO-mediated neurotoxicity. Accordingly,
PC12-pEGFP cells were incubated in either the absence (con-
trol) or presence of DETA-NO (0.5 mM; 1.4 M NO) for 60
min. At 10-min intervals, aliquots from the cell suspension
were analyzed for annexin V/propidium iodide cells by flow
cytometry. As shown in Fig. 7A, DETA-NO caused a rapid (20
min) and time-dependent increase (by 3-fold at 60 min) in the
proportion of apoptotic cells. To compare the differential sus-
ceptibility of G6PD modulation to NO-mediated apoptosis,
these cells were incubated in the presence of DETA-NO (0.5
mM) for 30 and 60 min and subjected to annexin V/propidium
iodide assessment. As shown in Fig. 7B, the proportion of
apoptotic PC12 cells increased by 1.9-fold after 30 min and by
1.5-fold after 60 min of incubation in the presence of DETA-
NO. Intriguingly, cells transfected with the vector alone (PC12-
pEGFP) showed higher susceptibility to DETA-NO (2.5- and
3-fold increase in apoptotic cells after 30 and 60 min, respec-
FIG. 6. Peroxynitrite transiently prevents nitric oxide-medi-
ated neuronal NADPH depletion, glutathione oxidation, and
apoptosis. Neurons were preincubated in the absence (control) or
presence of SIN-1 (1 mM) at 37 °C for 1 h in DMEM. After removal of the
SIN-1 solutions, the cells were washed with PBS and then further
incubated in either the absence (SIN-1  none) or presence (SIN-1 
DETA-NO) of DETA-NO (1 mM) in DMEM at 37 °C for 8 h. One group
of cells was not preincubated with SIN-1 and was incubated only in the
presence of DETA-NO (1 mM) (none  DETA-NO) for 8 h. NADPH
concentrations (A), total (GSx) and oxidized (GSSG) glutathione con-
centrations (B), and the proportion of apoptotic cells (% of annexin
V/propidium iodide (PI)) (C) were determined as described under
“Experimental Procedures.” Data are the means  S.E. obtained from
three to four different experiments. *, p  0.05 compared with the
corresponding control values; #, p  0.05 compared with the corre-
sponding none  DETA-NO values.
TABLE III
Peroxynitrite pretreatment prevents nitric oxide-mediated neuronal
apoptotic death
Neurons were preincubated with ONOO (10 pulses of 50 M for 5
min) or with a degraded solution of ONOO (0.5 mM; control) at 37 °C
for 5 min in buffered Hanks’ solution. After removal of the buffer, the
cells were washed with PBS and then further incubated in the presence
of DETA-NO (1 mM) at 37 °C in DMEM for 30 min. The proportion of
apopotic cells (% of annexin V/propidium iodide (PI)) was deter-
mined as described under “Experimental Procedures.” Data are the




Control (degraded solution of
0.5 mM ONOO)
16.9  0.1
DETA-NO (1 mM) 23.0  2.4a
ONOO (10 pulses of 50 M),
followed by DETA-NO (1 mM)
10.6  1.0b
a p  0.05 compared with control values.
b p  0.05 compared with DETA-NO values.
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tively). However, cells overexpressing the sense G6PD gene
(PC12-pEGFP-G6PD-sense) showed a remarkable resistance to
DETA-NO-mediated apoptotic cell death (Fig. 7B). In contrast,
cells overexpressing the antisense G6PD gene (PC12-pEGFP-
G6PD-antisense) showed marked enhanced susceptibility to
DETA-NO-mediated apoptotic cell death (3.8- and 5.6-fold
increase in apoptotic cells after 30 and 60 min, respectively)
(Fig. 7B). Intriguingly, expression of the vector alone (PC12-
pEGFP) slightly increased the proportion of apoptosis (Fig. 7B).
DISCUSSION
The correlation between rapid activation of PPP activity and
NADPH accumulation described here upon peroxynitrite treat-
ment confirms the well known NADPH-generating function of
the PPP (22). Due to its relatively low concentrations, NADP
availability alone could not account for NADPH accumulation.
However, the decrease in NAD concentrations brought about
by peroxynitrite suggests that NAD phosphorylation may pro-
vide sufficient NADP for ready conversion into NADPH
through G6PD activity (55–57). Accordingly, our data are com-
patible with the notion that peroxynitrite would stimulate
G6PD activity, as demonstrated by the increase in the 6-phos-
phogluconate/glucose 6-phosphate ratio by either exogenous or
endogenous peroxynitrite. This hypothesis was further exam-
ined in PC12 cells stably expressing plasmid constructs into
which the G6PD gene had been inserted in either the sense or
antisense orientation. As judged by the good correlation be-
tween the G6PD activity and NADPH concentrations observed
in these cells, our results confirm the idea that the modulation
of G6PD activity does dictate endogenous NADPH concentra-
tions (58, 59).
Previous studies carried out on several cell types have al-
ready suggested the essential role of PPP and/or G6PD activity
in cellular protection against H2O2-induced glutathione oxida-
tion (18–21, 23). Furthermore, our previous work carried out in
LPS-activated astrocytes (25) suggested a critical role for G6PD
induction in astrocyte autoprotection. However, the rapid acti-
vation of G6PD activity by peroxynitrite observed here rules
out any possible transcriptional effect. Because peroxynitrite
failed to alter total G6PD activity, we investigated whether any
changes in subcellular enzyme localization might be responsi-
ble for the rapid activation. In this context, previous work
focused on studying the regulation of G6PD activity by growth
factors in renal cells (42) has elegantly demonstrated that a
rapid stimulation of G6PD activity occurs through enzyme
release from a structural intracellular element. Our data from
Western blot analyses demonstrated that peroxynitrite trig-
gers G6PD release from both astrocytes and neurons, suggest-
ing that such a mechanism would be a feasible explanation for
the observed peroxynitrite-mediated G6PD activation.
Astrocytes have efficient self-protective systems, such as ac-
tive glycolytic (52, 60) and de novo glutathione-synthesizing
(13, 33, 53, 61) pathways or higher superoxide dismutase ex-
pression (62), which account for the resistance shown by glial
cells to a wide range of insults, including NO exposure (this
work). In contrast to astrocytes, neurons are vulnerable cells
that, upon exposure to either endogenous (9, 63) or exogenous
(52) excess NO, rapidly (within 1 h) undergo apoptotic death
(this study). Pretreatment of neurons with peroxynitrite fully
prevented apoptosis shortly (1 h) after NO treatment, although
this protection progressively decreased thereafter (to 60%
protection after 4 h and to 25% after 8 h). Furthermore, these
changes in peroxynitrite-mediated neuroprotection showed a
good time course correlation with the observed changes in the
glutathione redox status. Because glutathione oxidation has
been implicated in NO-mediated neuronal apoptosis (13, 63–
65), it is tempting to speculate that the neuroprotection exerted
by peroxynitrite would be associated with its ability to activate
PPP activity and to generate NADPH. Thus, during the period
of maximum protection (i.e. from 1 to 4 h after peroxynitrite
treatment), neuronal NADPH levels were 200–350 pmol/mg
of protein. Assuming a cell volume of 4 l/mg of protein (66),
the concentrations of NADPH would be 50–100 M, i.e.
within the published glutathione reductase km values for
NADPH (8–61 M for bovine brain; reviewed in Ref. 67).
Accordingly, it is likely that the maintenance of the reduced
status of GSH after peroxynitrite treatment would occur at the
expense of increased NADPH availability to serve as the cofac-
tor for glutathione reductase activity.
Because peroxynitrite-mediated neuroprotection against
NO would be associated with its ability to stimulate G6PD
activity, we were prompted to investigate the possible role
played by the modulation of G6PD gene expression in NO-
mediated apoptosis. Our results showed that PC12 cells ex-
pressing the sense G6PD gene offered remarkable resistance to
NO-mediated apoptosis, whereas cells expressing the anti-
sense G6PD gene showed a considerably higher susceptibility.
These results confirm the notion that G6PD activity would play
an essential role in preventing oxidative/nitrosative cellular
damage (23, 58, 59) and suggest a key role for G6PD in neuro-
FIG. 7. Overexpression of G6PD protects and inhibition of
G6PD enhances nitric oxide-mediated apoptotic death in PC12
cells. PC12 cells or PC12 cells stably expressing the vector alone
(PC12-pEGFP) or pEGFP mammalian plasmid vectors with the G6PD
gene inserted in either the sense (PC12-pEGFP-G6PD-sense) or anti-
sense (PC12-pEGFP-G6PD-antisense) orientation were incubated in
the absence (control) or presence of DETA-NO (0.5 mM) in Hanks’
solution at 37 °C for the time periods indicated. The proportion of
apoptotic cells (% of annexin V/propidium iodide (PI)) was deter-
mined by flow cytometry as described under “Experimental Proce-
dures.” Data are the means  S.E. obtained from three to four different
experiments. *, p  0.05 compared with the corresponding control
values; #, p  0.05 compared with PC12-pEGFP cells.
Neuroprotection by Peroxynitrite872
protection. However, it should be noted that, besides G6PD,
other well known NADPH-generating systems have also been
proposed to contribute to the protection against oxidative dam-
age, such as cytosolic NADP-dependent isocitrate dehydro-
genase (68), the PPP non-oxidative branch rate-limiting en-
zyme transaldolase (24), and NADP-dependent malic enzyme
(22). Whether peroxynitrite would be involved in the modula-
tion of such antioxidant systems is unknown and deserves
further research.
The transient neuroprotective role for peroxynitrite de-
scribed here is in apparent contradiction with the widely held
assumption that peroxynitrite would be the NO-derived neu-
rotoxic effector molecule (7–9, 17). Indeed, peroxynitrite inter-
feres with key energy-related targets, such as aconitase (69),
poly(ADP-ribose) synthetase (70–74), and mitochondrial respi-
ratory chain complexes (16, 17, 75, 76). Because neurons are
strong energy-demanding cells, these phenomena would affect
neuronal survival. In our hands, peroxynitrite failed to cause
neuronal apoptotic death up to 8 h. However, it was highly
cytotoxic when the incubation time was extended up to 24 h, in
good agreement with previous reports (9, 77). Therefore, the
relationship between peroxynitrite-mediated interference with
key energy-related metabolic targets and the time course of the
observed neurotoxicity is an issue that should be revisited. It is
also interesting to note that Clancy et al. (12) previously found
that exposure of human neutrophils to NO is associated with
O2
. removal, enhanced [1-14C]glucose oxidation, and GSH re-
generation. Furthermore, an increasing body of evidence now
suggests that NO might play a protective role against
O2
.-mediated neurotoxicity (78–81) and H2O2-mediated cyto-
toxicity (82, 83). In view of the spontaneous peroxynitrite for-
mation through the reaction of NO with O2
. (7) and in the light
of our own results, it is tempting to speculate that peroxynitrite
would mediate these NO-derived protective responses. Taken
together, our results may provide a clue for understanding the
existing controversy concerning the role of NO in cell death/
survival decisions.
In conclusion, we have show here that peroxynitrite plays a
novel neuroprotective role against NO-mediated apoptotic cell
death. The mechanism responsible for this phenomenon would
involve G6PD release from a structural intracellular element,
leading to enzyme activation, followed by NADPH generation
through PPP activity. The G6PD transgene approach con-
firmed the critical neuroprotective role played by this enzyme
against NO-mediated apoptosis. Furthermore, given the essen-
tial role of NADPH as a cofactor for glutathione regeneration,
our results may contribute to the elucidation of mechanisms
through which neurons would be able to protect themselves
against NO-mediated glutathione oxidation and apoptosis.
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